Search results for " Liver transplant"

showing 10 items of 77 documents

Long-Term Results After Liver Transplantation With “Livers That Nobody Wants” Within Eurotransplant: A Center's Experience

2008

Abstract Background Orthotopic liver transplantation (OLT) represents the only curative treatment for end-stage liver disease, but its application is limited because of organ shortages. The purpose of this study was to review the long-term outcomes after OLT during a 2-year period of 45 rescue offers organs within Eurotransplant. Patients and Methods Forty-five deceased donor liver allografts had been officially offered to and rejected by other transplantation centers 162 times prior to our acceptance. Data analysis addressed recurrence of primary disease, ischemic-type biliary lesions (ITBL), re-evaluation or relisting for OLT, re-OLT, as well as overall patient and graft survivals. Result…

AdultMaleReoperationmedicine.medical_specialtyOrthotopic liver transplantationmedicine.medical_treatmentLiver transplantationLiver diseaseCadavermedicineHumansTransplantation HomologousSurvivorsSurvival rateTransplantationbusiness.industryPatient SelectionGraft SurvivalHepatitis CLong term resultsMiddle Agedmedicine.diseaseTissue DonorsLiver TransplantationSurgerySurvival RateTransplantationTreatment Outcomesurgical procedures operativeFemaleSurgeryGraft survivalbusinessLiver FailureTransplantation Proceedings
researchProduct

Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the E…

2021

Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29 902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and liver transplantation era, adult PSC patients receiving LDLT showed increased mortality compare…

AdultMalemedicine.medical_specialtyBrain DeathCirrhosisMultivariate analysis[SDV]Life Sciences [q-bio]Medizinliving donorDiseaseAutoimmune hepatitisinflammatory030230 surgeryclinical research/practiceGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicinepatient survivalInternal medicinemedicinePrimary Sclerosing CholangitisLiving DonorsImmunology and AllergyRisk-FactorsHumansPharmacology (medical)RegistriesChildRetrospective StudiesTransplantationbusiness.industryLiver DiseasesHazard ratioGraft SurvivalCohort[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.disease3. Good healthDonation after brain deathLiver TransplantationTreatment Outcome030211 gastroenterology & hepatologyimmuneMorbidityLiving donor liver transplantationbusinessliver diseaseliver transplantation/hepatologyAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsREFERENCES
researchProduct

Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria

2008

Abstract Background Living donor liver transplantation (LDLT) represents an alternative to expand the organ pool for adult patients with hepatocellular carcinoma (HCC) and end-stage liver disease. The purpose of this study was to demonstrate our institutional experience using criteria exceeding those of the University of California San Francisco (UCSF). Patients and Methods Between September 1998 and December 2006, 22 LDLTs were performed for HCC among patients exceeding the UCSF criteria. Results There were 17 men and 5 women of median age 55 years. Multifocal tumors were present in 19 of 22 patients. Tumor grading was: grade I (n = 8), grade II (n = 10), and grade III (n = 4). Microvascul…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentMedizinLiver transplantationGastroenterologyDisease-Free SurvivalLiver diseaseInternal medicineLiving DonorsTumor GradingHumansMedicineIn patientSurvivorsNeoplasm StagingTransplantationbusiness.industryPatient SelectionLiver NeoplasmsCancerMiddle Agedmedicine.diseaseLiver TransplantationSurgerySurvival RateHepatocellular carcinomaFemaleSurgerybusinessLiver cancerLiving donor liver transplantationTransplantation Proceedings
researchProduct

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

2009

We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …

AdultMalemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentCalcineurin InhibitorsUrologyRENAL DYSFUNCTIONRenal functionCALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MYCOPHENOLATE MOFETIL; RENAL DYSFUNCTIONLiver transplantationKidney Function TestsTacrolimusMycophenolic acidNephrotoxicitychemistry.chemical_compoundmedicineHumansMYCOPHENOLATE MOFETILAgedTransplantationCreatinineIMMUNOSUPPRESSIONDose-Response Relationship Drugbusiness.industryGraft SurvivalMiddle AgedMycophenolic AcidTacrolimusLiver TransplantationCalcineurinliver transplantTreatment OutcomechemistryCreatinineImmunologyKidney Failure ChronicDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsGlomerular Filtration Ratemedicine.drug
researchProduct

Use of Hepatitis C-Positive Deceased Liver Donors in Response to the Organ Shortage in an Endemic Area

2017

The region of Sicily, Italy, is witnessing a chronic organ shortage. Thus, to face this critical issue, the use of marginal donors has increased over time. An example of marginal donor expansion is the use of liver donors who are positive for the hepatitis C antibody (HCV+) for HCV+ patients requiring liver transplantation (LT). In view of new advances in HCV therapy, including direct-acting agents (DAAs) to treat HCV in the post-transplant setting, our study focused on a monocentric experience in a series of consecutive LTs performed in adult patients receiving HCV+ liver donor allografts. From 2003 to 2016 at our institute we performed 10 LT using HCV+ deceased donors. In particular, the …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepacivirusHepacivirusLiver transplantationAntiviral AgentsGastroenterologyDonor SelectionFibrosisInternal medicinemedicineHumansAntiviral Agents; Donor Selection; Hepacivirus; Liver TransplantationSurvival rateAgedRetrospective StudiesTransplantationbiologybusiness.industryDonor selectionGraft SurvivalGeneral MedicineHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CTissue DonorsIshak ScoreLiver TransplantationSurvival RateItalyLiverFemaleSteatosisbusinessAntiviral agents Donor selection Hepacivirus Liver transplantation Adult Graft Survival Hepatitis C Liver Liver Transplantation Middle Aged Retrospective Studies Survival Rate Tissue DonorsAnnals of Transplantation
researchProduct

Liver "Compliance": A previously unrecognized preoperative predictor of small-for-size syndrome in adult living donor liver transplantation

2008

The purpose of this study was to investigate the effect of liver compliance on computed tomography (CT) volumetry and to determine its association with postoperative small-for-size syndrome (SFSS).Unenhanced, arterial, and venous phase CT images of 83 consecutive living liver donors who underwent graft hepatectomy for adult-to-adult living donor liver transplantation (ALDLT) were prospectively subjected to three-dimensional (3-D) CT liver volume calculations and virtual 3-D liver partitioning. Graft volume estimates based on 3-D volumetry, which subtracted intrahepatic vascular volume from the "smallest" (native) unenhanced and the "largest" (venous) CT phases, were subsequently compared wi…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationHepatic VeinsliverLiver massLiver ctUser-Computer InterfacemedicineLiving DonorsHumansSurvivorsRetrospective StudiesTransplantationSmall for size syndromebusiness.industryMortality rateBody WeightOrgan SizeMiddle AgedSurvival AnalysisLiver TransplantationCompliance (physiology)Tissue and Organ HarvestingSurgeryFemaleRadiologyHepatectomyLiving donor liver transplantationbusinessTomography X-Ray Computed
researchProduct

Outcomes of Liver Transplant for Adults With Wilson’s Disease

2020

Wilson's disease (WD) is a rare genetic disorder with protean manifestations. Even if liver transplantation (LT) could represent an effective therapeutic option for patients with end-stage liver disease, it has remained controversial in the presence of neuropsychiatric involvement. This study aimed to examine the frequency of adult LT for WD in Italy, focusing on the disease phenotype at the time of LT. A retrospective, observational, multicenter study was conducted across Italy exploring the frequency and characteristics of adults transplanted for WD between 2006 and 2016. A total of 29 adult WD patients underwent LT during the study period at 11 Italian LT centers (accounting for 0.4% of …

AdultMalewilson disease liver transplantationmedicine.medical_specialtymedicine.medical_treatmentwilson diseaseDisease030230 surgeryLiver transplantationSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineHepatolenticular DegenerationInternal medicineAcute on chronic liver failuremedicineHumansRetrospective StudiesTransplantationHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAWilsonGenetic disorderPatient survivalmedicine.diseaseLong-term outcomeLiver TransplantationNeuropsychiatric symptomsWilson's diseaseTreatment OutcomeItalyCirrhosisMulticenter studyAcute on chronic liver failure; Cirrhosis; Long-term outcome; Neuropsychiatric symptomsFemale030211 gastroenterology & hepatologySurgerybusinessNeurological impairmentLiver Transplantation
researchProduct

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

2021

Simple Summary Intrahepatic cholangiocarcinoma is a rare disease with increasing incidence and mortality still characterized by an insufficient clinical outcome. Growing attention has recently surrounded this disease, and liver transplantation has emerged as a novel curative treatment for cholangiocarcinoma, along with a better understanding of genetic alterations potentially capable of driving tumorigenesis. The aim of this paper is to present a clinical description of our case series of patients affected by intrahepatic cholangiocarcinoma and by mixed forms of hepatocellular and cholangiocellular carcinoma, together with a genomic profiling of mutations occurring in a panel of genes relev…

Cancer ResearchLiver tumorliver transplantationbusiness.industrymedicine.medical_treatmentWnt signaling pathwayCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensLiver transplantationmedicine.diseasemedicine.disease_causeArticlenext-generation sequencing.Oncologyintrahepatic cholangiocarcinomamedicineCancer researchnext-generation sequencingKRASCarcinogenesisbusinessPI3K/AKT/mTOR pathwayIntrahepatic CholangiocarcinomaRC254-282intrahepatic cholangiocarcinoma; liver transplantation; next-generation sequencingCancers
researchProduct

Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after live…

2022

BackgroundThough the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.MethodsWe retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT…

Cancer ResearchneoangiogenesisimmunocytochemistryrecurrenceOncologyliver transplantationneoangiogenesiangiopoietin-2hepatocellular carcinomaangiopoietin-2; hepatocellular carcinoma; immunocytochemistry; liver transplantation; neoangiogenesis; recurrence; survivalsurvival
researchProduct